Consistently, TLR2 ligand Pam3CSK4 application in vivo with transferred tumor antigen (Ag)-specific CD8+ T cells results in enhanced therapeutic efficacy of these CD8+ T cells in tumor models [74, 75]. Here, TLR2 is linked to neoplasm.